445 related articles for article (PubMed ID: 7526543)
1. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
[TBL] [Abstract][Full Text] [Related]
2. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice.
Boudet F; Theze J; Zouali M
Virology; 1994 Apr; 200(1):176-88. PubMed ID: 7510435
[TBL] [Abstract][Full Text] [Related]
3. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
4. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
5. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
6. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
7. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
8. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
Vogel T; Kurth R; Norley S
J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
[TBL] [Abstract][Full Text] [Related]
9. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
Gorny MK; Xu JY; Karwowska S; Buchbinder A; Zolla-Pazner S
J Immunol; 1993 Jan; 150(2):635-43. PubMed ID: 7678279
[TBL] [Abstract][Full Text] [Related]
10. Permissive residues within the minimal epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV-1.
Laisney IL; Benjamin H; Gefter M; Strosberg AD
Eur J Immunol; 1996 Jul; 26(7):1634-40. PubMed ID: 8766572
[TBL] [Abstract][Full Text] [Related]
11. CD4-imitating human antibodies in HIV infection and anti-idiotypic vaccination.
Deckert PM; Ballmaier M; Lang S; Deicher H; Schedel I
J Immunol; 1996 Jan; 156(2):826-33. PubMed ID: 8543839
[TBL] [Abstract][Full Text] [Related]
12. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
Zvi A; Feigelson DJ; Hayek Y; Anglister J
Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
[TBL] [Abstract][Full Text] [Related]
13. Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage. The V3 loop of HIV-1 gp120.
di Marzo Veronese F; Willis AE; Boyer-Thompson C; Appella E; Perham RN
J Mol Biol; 1994 Oct; 243(2):167-72. PubMed ID: 7523682
[TBL] [Abstract][Full Text] [Related]
14. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits.
Fung MS; Sun CR; Liou RS; Gordon W; Chang NT; Chang TW; Sun NC
J Immunol; 1990 Oct; 145(7):2199-206. PubMed ID: 2398276
[TBL] [Abstract][Full Text] [Related]
16. Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission.
Pantaleo G; Demarest JF; Vaccarezza M; Graziosi C; Bansal GP; Koenig S; Fauci AS
Eur J Immunol; 1995 Jan; 25(1):226-31. PubMed ID: 7843235
[TBL] [Abstract][Full Text] [Related]
17. Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1).
Laisney IL; Strosberg AD
Immunol Lett; 1999 Apr; 67(3):185-92. PubMed ID: 10369125
[TBL] [Abstract][Full Text] [Related]
18. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
[TBL] [Abstract][Full Text] [Related]
19. Anti-idiotypic antibody to the V3 domain of gp120 binds to vimentin: a possible role of intermediate filaments in the early steps of HIV-1 infection cycle.
Thomas EK; Connelly RJ; Pennathur S; Dubrovsky L; Haffar OK; Bukrinsky MI
Viral Immunol; 1996; 9(2):73-87. PubMed ID: 8822624
[TBL] [Abstract][Full Text] [Related]
20. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
Laman JD; Schellekens MM; Lewis GK; Moore JP; Matthews TJ; Langedijk JP; Meloen RH; Boersma WJ; Claassen E
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):605-12. PubMed ID: 8369165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]